AAVelocity

From The Korea Economic Daily: SK pharmteco Launches New Viral Vector Platforms, Key for CGT

News / By

The Korean CDMO’s new viral vector platforms can significantly save the production time and cost of AAV and lentiviral vectors By Ji-Hyun Lee SK pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two new viral vector platforms that are expected to save the time and cost of […]

From The Korea Economic Daily: SK pharmteco Launches New Viral Vector Platforms, Key for CGT Read More »

SK pharmteco’s subsidiary Yposkesi launches AAVelocity, a plug-and-play Adeno-Associated Virus (AAV) platform

News / By

Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use Evry-Courcouronnes (near Paris), France, November 7, 2023 – Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C&GT), today launches AAVelocityTM,

SK pharmteco’s subsidiary Yposkesi launches AAVelocity, a plug-and-play Adeno-Associated Virus (AAV) platform Read More »

Links
Compliance
Twitter Linkedin-in Facebook-square
Copyright ©2024 by SK pharmteco Inc. All Rights Reserved
Scroll to Top

Enter your details to access Marketing Materials

"*" indicates required fields